A new way to estimate neurologic disease prevalence in the United States: Illustrated with MS

A new way to estimate neurologic disease prevalence in the United States: Illustrated with MS

Lorene M. Nelson, PhD, MS,corresponding author Mitchell T. Wallin, MD, MPH, Ruth Ann Marrie, MD, PhD, W.J. Culpepper, PhD, Annette Langer-Gould, MD, PhD, Jon Campbell, PhD, Stephen Buka, ScD, Helen Tremlett, PhD, Gary Cutter, PhD, Wendy Kaye, PhD, Laurie Wagner, MPH, Nicholas G. Larocca, PhD, and for the United States Multiple Sclerosis Prevalence Workgroup


Abstract

Objective

Considerable gaps exist in knowledge regarding the prevalence of neurologic diseases, such as Multiple Sclerosis (MS), in the United States. Therefore, the MS Prevalence Working Group sought to review and evaluate alternative methods for obtaining a scientifically valid estimate of national MS prevalence in the current health care era.

Methods

We carried out a strengths, weaknesses, opportunities, and threats (SWOT) analysis for 3 approaches to estimate MS prevalence: population-based MS registries, national probability health surveys, and analysis of administrative health claims databases. We reviewed MS prevalence studies conducted in the United States and critically examined possible methods for estimating national MS prevalence.

Results

We developed a new 4-step approach for estimating MS prevalence in the United States. First, identify administrative health claim databases covering publicly and privately insured populations in the United States. Second, develop and validate a highly accurate MS case-finding algorithm that can be standardly applied in all databases. Third, apply a case definition algorithm to estimate MS prevalence in each population. Fourth, combine MS prevalence estimates into a single estimate of US prevalence, weighted according to the number of insured persons in each health insurance segment.

Conclusions:  By addressing methodologic challenges and proposing a new approach for measuring the prevalence of MS in the United States, we hope that our work will benefit scientists who study neurologic and other chronic conditions for which national prevalence estimates do not exist.
Much more to read if you click here


.................................................................................................

CLICK Red BOX to SUBSCRIBE to the MS Learning Channel on YouTube

antidepressant
Click Red Box on banner to opt-in
........................................................................................................

This Article is Provided by:  #MSViewsandNews
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
antidepressant
(Originally posted by Stuart)
A Framework for Estimating the Burden of Chronic D...
Long term effect of delayed treatment on disabilit...
 

Comments

No comments made yet. Be the first to submit a comment
Already Registered? Login Here
Guest
Wednesday, 01 April 2020

Captcha Image


 
 

Follow Us on Twitter

Follow Us On Twitter - Image